InsiderTrades.com logo

Patrick Lin Biography and Net Worth

Insider of Processa Pharmaceuticals
  • Phone
  • Email
  • Website


Mr. Lin has over 20 years of financing and investing experience in the Biopharm Sector. He was Co-Founder and Chairman of the Board of Promet Therapeutics, LLC . He is Founder and Managing Partner of Primarius Capital, a family office that manages public and private investments focused on small capitalization companies. For 10 years prior to forming Primarius Capital, Mr. Lin worked at several Wall Street banking and brokerage firms including Robertson Stephens & Co., E*Offering, and Goldman Sachs & Co. Mr. Lin was Co-Founding Partner of E*Offering.

Mr. Lin received an MBA from Kellogg Graduate School of Management, a Master of Engineering Management, and a Bachelor of Science in Business Administration from the University of Southern California.

What is Patrick Lin's net worth?

The estimated net worth of Patrick Lin is at least $10,702.94 as of January 31st, 2024. Mr. Lin owns 25,978 shares of Processa Pharmaceuticals stock worth more than $10,703 as of April 2nd. This net worth evaluation does not reflect any other assets that Mr. Lin may own. Additionally, Mr. Lin receives a salary of $117,150.00 as Insider at Processa Pharmaceuticals. Learn More about Patrick Lin's net worth.

How old is Patrick Lin?

Mr. Lin is currently 59 years old. There are 5 older executives and no younger executives at Processa Pharmaceuticals. The oldest executive at Processa Pharmaceuticals is Dr. David Young Ph.D., Pharm.D., Co-Founder, President of Research and Development & Director, who is 71 years old. Learn More on Patrick Lin's age.

What is Patrick Lin's salary?

As the Insider of Processa Pharmaceuticals, Inc., Mr. Lin earns $117,150.00 per year. There are 4 executives that earn more than Mr. Lin. The highest earning executive at Processa Pharmaceuticals is Mr. George K. Ng Esq., J.D., CEO & Director, who commands a salary of $402,030.00 per year. Learn More on Patrick Lin's salary.

How do I contact Patrick Lin?

The corporate mailing address for Mr. Lin and other Processa Pharmaceuticals executives is 7380 COCA COLA DRIVE SUITE 106, HANOVER MD, 21076. Processa Pharmaceuticals can also be reached via phone at (443) 776-3133 and via email at plin@processapharma.com. Learn More on Patrick Lin's contact information.

Has Patrick Lin been buying or selling shares of Processa Pharmaceuticals?

Patrick Lin has not been actively trading shares of Processa Pharmaceuticals over the course of the past ninety days. Most recently, on Wednesday, January 31st, Patrick Lin bought 2,500 shares of Processa Pharmaceuticals stock. The stock was acquired at an average cost of $2.37 per share, with a total value of $5,925.00. Following the completion of the transaction, the insider now directly owns 25,978 shares of the company's stock, valued at $61,567.86. Learn More on Patrick Lin's trading history.

Who are Processa Pharmaceuticals' active insiders?

Processa Pharmaceuticals' insider roster includes Robert Floyd (COO), Patrick Lin (Insider), James Stanker (CFO), Justin Yorke (Director), and David Young (CEO). Learn More on Processa Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Processa Pharmaceuticals?

During the last year, Processa Pharmaceuticals insiders bought shares 3 times. They purchased a total of 224,100 shares worth more than $179,280.00. The most recent insider tranaction occured on January, 27th when CEO George K Ng bought 87,200 shares worth more than $69,760.00. Insiders at Processa Pharmaceuticals own 13.0% of the company. Learn More about insider trades at Processa Pharmaceuticals.

Information on this page was last updated on 1/27/2025.

Patrick Lin Insider Trading History at Processa Pharmaceuticals

See Full Table

Patrick Lin Buying and Selling Activity at Processa Pharmaceuticals

This chart shows Patrick Lin's buying and selling at Processa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$5k$0$5kTotal Insider BuyingTotal Insider Selling

Processa Pharmaceuticals Company Overview

Processa Pharmaceuticals logo
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.
Read More

Today's Range

Now: $0.41
Low: $0.36
High: $0.46

50 Day Range

MA: $0.53
Low: $0.37
High: $0.73

2 Week Range

Now: $0.41
Low: $0.36
High: $3.31

Volume

878,362 shs

Average Volume

768,971 shs

Market Capitalization

$2.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75